CY1117654T1 - Πολυαιθυλενογλυκολιωμενη απελινη και χρησεις αυτης - Google Patents

Πολυαιθυλενογλυκολιωμενη απελινη και χρησεις αυτης

Info

Publication number
CY1117654T1
CY1117654T1 CY20161100447T CY161100447T CY1117654T1 CY 1117654 T1 CY1117654 T1 CY 1117654T1 CY 20161100447 T CY20161100447 T CY 20161100447T CY 161100447 T CY161100447 T CY 161100447T CY 1117654 T1 CY1117654 T1 CY 1117654T1
Authority
CY
Cyprus
Prior art keywords
polyethylene
glyclened
apreline
apelin
disorders
Prior art date
Application number
CY20161100447T
Other languages
English (en)
Inventor
Zhiqiang JIA
Lihui HOU
Clark Q. Pan
Geoffrey Y. Akita
Original Assignee
Genzyme Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corporation filed Critical Genzyme Corporation
Publication of CY1117654T1 publication Critical patent/CY1117654T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Η εφεύρεση παρέχει συνθέσεις και μεθόδους για τη θεραπεία μίας ασθένειας ή διαταραχής που σχετίζεται με την Απελίνη. Ειδικότερα, η εφεύρεση αναφέρεται σε μία πολυαιθυλενογλυκολιωμένη μορφή της Απελίνης, ώστε να παρέχει έναν εκτεταμένο χρόνο κυκλοφορίας και φαινόμενα ινοτροπισμού και, με τον τρόπο αυτό, να θεραπεύονται αποτελεσματικά οι ασθένειες ή διαταραχές που σχετίζονται με την Απελίνη.
CY20161100447T 2011-03-11 2016-05-24 Πολυαιθυλενογλυκολιωμενη απελινη και χρησεις αυτης CY1117654T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161451623P 2011-03-11 2011-03-11
PCT/US2012/028298 WO2012125408A1 (en) 2011-03-11 2012-03-08 Pegylated apelin and uses thereof

Publications (1)

Publication Number Publication Date
CY1117654T1 true CY1117654T1 (el) 2018-03-07

Family

ID=46831054

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161100447T CY1117654T1 (el) 2011-03-11 2016-05-24 Πολυαιθυλενογλυκολιωμενη απελινη και χρησεις αυτης

Country Status (14)

Country Link
US (1) US20140142049A1 (el)
EP (2) EP2683360B1 (el)
AU (2) AU2012229336B2 (el)
CA (1) CA2829693C (el)
CY (1) CY1117654T1 (el)
DK (2) DK2683360T3 (el)
ES (2) ES2690147T3 (el)
HR (2) HRP20160547T1 (el)
HU (1) HUE027579T2 (el)
LT (1) LT3045183T (el)
PL (2) PL3045183T3 (el)
PT (1) PT3045183T (el)
SI (2) SI3045183T1 (el)
WO (1) WO2012125408A1 (el)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3045183T1 (sl) 2011-03-11 2018-11-30 Genzyme Corporation Pegiliran Apelin in njegove uporabe
WO2014099984A1 (en) * 2012-12-20 2014-06-26 Amgen Inc. Apj receptor agonists and uses thereof
US9353163B2 (en) * 2013-03-14 2016-05-31 Regeneron Pharmaceuticals, Inc. Apelin fusion proteins and uses thereof
WO2015013165A1 (en) * 2013-07-25 2015-01-29 Novartis Ag Cyclic apelin derivatives for the treatment of heart failure
KR20160031551A (ko) 2013-07-25 2016-03-22 노파르티스 아게 심부전의 치료를 위한 시클릭 폴리펩티드
AU2014293387B2 (en) 2013-07-25 2017-04-20 Novartis Ag Bioconjugates of synthetic apelin polypeptides
US9683018B2 (en) * 2013-07-25 2017-06-20 Novartis Ag Disulfide cyclic polypeptides for the treatment of heart failure
EA201691027A1 (ru) 2013-11-20 2016-12-30 Ридженерон Фармасьютикалз, Инк. Модуляторы aplnr и их применение
ES2719137T3 (es) 2014-03-25 2019-07-08 Lanthiopep Bv Análogos de apelina cíclica
CA2951391C (en) * 2014-06-10 2021-11-02 Amgen Inc. Apelin polypeptides
EA201791668A1 (ru) 2015-01-23 2017-11-30 Новартис Аг Синтетические конъюгаты апелина с жирной кислотой с улучшенным периодом полураспада
WO2018075822A1 (en) 2016-10-19 2018-04-26 Avive, Inc. Novel pegylated liposomal formulations of apelin for treatment of cardiovascular-related diseases
WO2021255282A1 (en) * 2020-06-18 2021-12-23 Universite D'aix Marseille Conjugated and labelled apelin, preparation and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6420339B1 (en) * 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
ATE471722T1 (de) * 2003-03-12 2010-07-15 Univ Arizona State Verfahren zur regulierung von angiogenese mit apelin-zusammensetzungen
US7947280B2 (en) * 2003-05-22 2011-05-24 The Board Of Trustees Of The Leland Stanford Junior University Apelin and uses thereof
US20090286723A1 (en) * 2005-02-11 2009-11-19 Amylin Pharmaceuticals, Inc. Hybrid Polypeptides with Selectable Properties
US20090252703A1 (en) * 2006-10-19 2009-10-08 Gegg Jr Colin V Use of alcohol co-solvents to improve pegylation reaction yields
SI3045183T1 (sl) 2011-03-11 2018-11-30 Genzyme Corporation Pegiliran Apelin in njegove uporabe

Also Published As

Publication number Publication date
EP2683360B1 (en) 2016-02-24
HRP20160547T1 (hr) 2016-06-17
WO2012125408A1 (en) 2012-09-20
ES2690147T3 (es) 2018-11-19
CA2829693C (en) 2020-04-21
EP2683360A4 (en) 2014-09-03
PL2683360T3 (pl) 2016-09-30
AU2017202919A1 (en) 2017-05-25
LT3045183T (lt) 2018-10-25
EP3045183B1 (en) 2018-07-04
SI2683360T1 (sl) 2016-06-30
AU2017202919B2 (en) 2019-03-14
HUE027579T2 (en) 2016-10-28
HRP20181589T1 (hr) 2018-12-28
US20140142049A1 (en) 2014-05-22
SI3045183T1 (sl) 2018-11-30
AU2012229336B2 (en) 2017-02-02
AU2012229336A1 (en) 2013-10-10
CA2829693A1 (en) 2012-09-20
EP2683360A1 (en) 2014-01-15
DK3045183T3 (en) 2018-10-22
ES2573337T3 (es) 2016-06-07
PL3045183T3 (pl) 2018-12-31
PT3045183T (pt) 2018-11-02
DK2683360T3 (en) 2016-05-30
WO2012125408A8 (en) 2018-01-25
EP3045183A1 (en) 2016-07-20

Similar Documents

Publication Publication Date Title
CY1117654T1 (el) Πολυαιθυλενογλυκολιωμενη απελινη και χρησεις αυτης
CY1124144T1 (el) Συνθεσεις και μεθοδοι για θεραπεια εγκεφαλικου επεισοδιου σε ενα υποκειμενο επι ταυτοχρονης θεραπειας στατινης
CY1124311T1 (el) Παρεμποδιστες dna-pk
CY1125436T1 (el) Αναστολεις dna-pk
CY1120246T1 (el) Ενωσεις αναστολεων μεταλλοενζυμου
CY1124298T1 (el) Φενφλουραμινη για χρηση στην θεραπευτικη αντιμετωπιση του συνδρομου dravet
CY1122480T1 (el) Μεθυλικη βαρδοξολονη για τη θεραπεια παχυσαρκιας
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
CY1122186T1 (el) Μεθοδοι θεραπειας καρκινου
CY1121906T1 (el) Μεθοδος για τη θεραπεια της ατοπικης δερματιτιδας μεσω της χορηγησης ενος ανταγωνιστη toy il-4r
CY1122909T1 (el) Μεθοδοι αντιμετωπισης της ηωσινοφιλικης οισοφαγιτιδας με χορηγηση αναστολεα του ιl-4r
CY1121065T1 (el) Αναστολεις ιβατ για την αγωγη ηπατικων νοσων
CY1124926T1 (el) Νανοσωματιδια που περιλαμβανουν σιρολιμους και μια αλβουμινη για χρηση στη θεραπεια ογκων απο επιθηλιοειδη κυτταρα
CY1117678T1 (el) Ενωσεις αναστολεων μεταλλοενζυμου
CY1123051T1 (el) Ταπενταδολη για προληψη και θεραπεια καταθλιψης και αγχους
CY1120177T1 (el) Φλαγκελλινη roseburia και ανοσορυθμιση
CY1120729T1 (el) Πεπτιδια και συνθεσεις για τη θεραπεια τραυματισμου των αρθρωσεων
CY1120419T1 (el) Ενισχυση της μεταφορας θεραπευτικων μοριων μεσω του αιματοεγκεφαλικου φραγμου
CY1119167T1 (el) Αναστολεις toy nkcc για τη θεραπεια του αυτισμου
CY1121710T1 (el) Παρεμβασεις με βαση την αγγειοποιητινη για τη θεραπεια της εγκεφαλικης ελονοσιας
CR20150046A (es) Anticuerpos anti-cd79b e inmunoconjugados
CY1121849T1 (el) Μεθοδοι και συνθεσεις για τη θεραπεια του καρκινου
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
CY1120751T1 (el) Αναστολεις ετεροδικυκλοαρυλιου του rorc2 και μεθοδοι χρησης αυτων
CR20150047A (es) Anticuerpos anti-cd22 e inmunoconjugados